SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?


To: Cacaito who wrote (10262)5/28/1999 10:22:00 PM
From: aknahow  Read Replies (1) | Respond to of 17367
 
Never got to the p value. Helped to make several guesses. Also posted 34 for required number.

The information Nell and Grote is on the XOMA web and has been for a few days.

I am very happy XOMA provided us with the information. It would have been horrible to continue



To: Cacaito who wrote (10262)5/29/1999 9:52:00 AM
From: Robert K.  Respond to of 17367
 
Cacaito> interesting study just published in the Lancet
>>>>>>>>>Endotoxin and chronic heart faiulre.>>>>>
Wonder how they might applt this new info.
>here is a paragraph on it
"This study shows the presence of raised plasma endotoxin concentrations in patients with chronic heart failure and peripheral oedema. In the presence of unchanged concentrations of endotoxin binding protein, the raised endotoxin concentration reflects a potentially pathogenic situation that leads to cytokine induction. We show that normalisation of endotoxin concentrations can be achieved by intensified diuretic treatment. Bacterial endotoxin may be an important stimulus of immune activation in patients with chronic heart failure. Our studies are preliminary and further investigations are needed. Nevertheless, these findings may open various new options for treatment directed against bacteria in the bowel, the translocation process, and endotoxin itself, the binding sites of bacterial endotoxin on immune competent cells, or both. "